Drugs / Songling Xuemaikang Capsule
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07271732 | Dec 2025 → Dec 2026 expected | cerebrovascular disorder, hypertensive disorder | Dongzhimen Hospital, Beijing | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Songling Xuemaikang Capsule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07271732 ↗ |
| Known as | SXC | “Existing studies have shown that Songling Xuemaikang capsule (SXC) combined with antihypertensive drugs exerted significant effects on systolic blood pressure (SBP), diastolic...” NCT07271732 ↗ |
| Route | Oral | “p.o” NCT07271732 ↗ |